122 related articles for article (PubMed ID: 7327902)
1. Study of hydroxyproline excretion in patients with prostatic cancer.
Romics I; Budavári I; Kisbenedek L; Balogh F
Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
[TBL] [Abstract][Full Text] [Related]
2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
3. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
[TBL] [Abstract][Full Text] [Related]
4. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
Rinsho K; Aoyagi K
Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
[TBL] [Abstract][Full Text] [Related]
5. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
[No Abstract] [Full Text] [Related]
6. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
[TBL] [Abstract][Full Text] [Related]
7. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
[No Abstract] [Full Text] [Related]
8. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
[No Abstract] [Full Text] [Related]
9. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
O'Brien WM; Lynch JH
J Urol; 1988 Jan; 139(1):66-8. PubMed ID: 3121868
[TBL] [Abstract][Full Text] [Related]
10. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
Mooppan MM; Wax SH; Kim H; Wang JC; Tobin MS
J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
[TBL] [Abstract][Full Text] [Related]
11. [Excretion of urinary hydroxyproline in urinary tract diseases].
Guarino A; Comar OB; Taccone W; Cicalese V
Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
[TBL] [Abstract][Full Text] [Related]
12. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
Heller W; Harzmann R; Bichler KH; Schmidt K
Curr Probl Clin Biochem; 1979; (9):249-56. PubMed ID: 446076
[TBL] [Abstract][Full Text] [Related]
13. Urinary hydroxyproline levels in patients with prostatic carcinoma.
Erol D; Adalar N; Güvençli S; Simşek F
Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
[TBL] [Abstract][Full Text] [Related]
14. Urinary hydroxyproline excretion in patients with cancer.
Guzzo CE; Pachas WN; Pinals RS; Krant MJ
Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
[No Abstract] [Full Text] [Related]
15. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
[TBL] [Abstract][Full Text] [Related]
16. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
Gasser AB; Jeannet C; Depierre D; Courvoisier B
Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
[TBL] [Abstract][Full Text] [Related]
17. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
Hopkins SC; Palmieri GM; Niell HB; Moinuddin M; Soloway MS
Cancer; 1984 Jan; 53(1):117-21. PubMed ID: 6689994
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyproline excretion in malignant neoplastic disease.
Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
[No Abstract] [Full Text] [Related]
19. Serum osteocalcin concentration in patients with prostatic cancer.
Francini G; Bigazzi S; Leone V; Gennari C
Am J Clin Oncol; 1988; 11 Suppl 2():S83-7. PubMed ID: 3266542
[TBL] [Abstract][Full Text] [Related]
20. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
Bishop MC; Fellows GJ
Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
